Re(CO)3(H2O)3+ binding to lysozyme: structure and reactivity

Binkley, Sarah L.; Leeper, Thomas C.; Rowlett, Roger S.; Herrick, Richard S.; Ziegler, Christopher J.

doi:10.1039/c1mt00065a

Cited by 34 publications

(38 citation statements)

References 47 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast with cisplatin, the binding with the DNA bases is reversible (13). Re also binds with proteins (14,15). However, other properties of Re compounds have been identified, like the inhibition of some cysteine proteases (16).…”

mentioning

confidence: 99%

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Collery

Santoni

Ciccolini

et al. 2016

View full text Add to dashboard Cite

Abstract. Rhenium (I)-diselenoether has shown promising antiproliferative efficacy in both in vitro and in vivo models. However, the maximal tolerated dose and dose-effect relationships have not been fully addressed for this compound. Here, we evaluated the tolerance and efficacy of three dose-levels (namely 10, 40 and 100 mg/kg) intraperitoneally administered daily over 28 days in mice bearing the resistant MDA-MB231 breast cancer cell line.The upper dose was found to be toxic and was reduced to 60 mg/kg. The 10 mg/kg dose well tolerated, whereas 40 mg/kg was associated with 10% mortality (LD 10 ). Both 10 and 40 mg/kg dosing achieved a significantly similar regression of tumor growth compared with untreated animals. This study suggests that 10 mg/kg daily is the recommended dose for rhenium (I) diselenoether.Rhenium(I)-diselenoether has been proposed as an anticancer agent (1-6). This compound features a central atom of rhenium bound to 3,7-diselenanonanedioic acid ligand in which the two selenium atoms secure a tight complexation of the Re, while the carboxylic group, as sodium salt, allows water solubility. This amphiphilic complex is a hydrophilic drug, soluble in water, easy to administer and lipophilic with a good distribution in tissues after oral administration (2).Re is a heavy transition metal (atomic number 75, atomic mass 186.21 g/mol), with the widest range of oxidation states of any element (−3, −1, +1, +2, +3, +4, +5, +6 +7), providing it with unique properties. It was demonstrated with Re-diselenoether drug that Re formed DNA adducts with one or two guanine bases (3), like cisplatin, but with an octahedral configuration and not a square-planar one. The uptake of Re in the nucleus of malignant cells has also been demonstrated after exposure to Re-diselenoether complex (2). Other Re-based drugs have also shown a high activity against a variety of tumor cell lines, with a good selectivity for cancer cells (7,8). One common mechanism of action could be related to the binding of Re with guanine and adenine bases of DNA (9-12). In contrast with cisplatin, the binding with the DNA bases is reversible (13). Re also binds with proteins (14,15). However, other properties of Re compounds have been identified, like the inhibition of some cysteine proteases (16). We hypothesize that the Re atom could be used either for oxidation or reduction of cell components due to its great number of oxidation states. Re cluster compounds were screened for their biological activities as antioxidants (17) and proposed to protect erythrocytes from hemolytic anemia (18). These Re compounds affected the peroxidation level, the activity of superoxide dismutase, the antioxidant factor and the index of resistance of erythrocytes to hemolysis as a function of the concentration range in the pre-incubation medium of erythrocytes (19,20 (22) and with dichlorotetra-μ-isobutyratodirhenium (III) complex (23) and the cluster Re compound with gamma-aminobutyric acid ligand (24). This synergism was however not observed with the Re (I)-di...

show abstract

mentioning

confidence: 99%

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Collery

Santoni

Ciccolini

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In fact the original purpose for which amino acids containing an azide group has been designed was "click" chemistry, and consequently one may also add metal-carbonyl complexes with even stronger C≡O bands to it in a post-translational coupling step as a second alternative [48]. Finally, Re-carbonyl or Ru-carbonyl complexes have been bound selectively to histidines [30,[56][57][58].…”

Section: Advancing the Selectivitymentioning

confidence: 99%

Fast infrared spectroscopy of protein dynamics: advancing sensitivity and selectivity

Koziol

Johnson

Stucki-Buchli

et al. 2015

Current Opinion in Structural Biology

View full text Add to dashboard Cite

2D-IR spectroscopy has matured to a powerful technique to study the structure and dynamics of peptides, but its extension to larger proteins is still in its infancy, the major limitations being sensitivity and selectivity. Site-selective information requires measuring single vibrational probes at sub-millimolar concentrations where most proteins are still stable, which is a severe challenge for conventional (FT)IR spectroscopy. Besides its ultrafast time-resolution, a so far largely underappreciated potential of 2D-IR spectroscopy lies in its sensitivity gain. The present paper sets the goals and outlines strategies how to use that sensitivity gain together with properly designed vibrational labels to make IR spectroscopy a versatile tool to study a wide class of proteins. Abstract Abstract: 2D-IR spectroscopy has matured to a powerful technique to study the structure

show abstract

“…This secondary metabolite, chromone and its derivatives are known to induce cytotoxic effects in breast cancer cell lines [13,14]. Hence, we report the coordination reactions of [Re(CO) 5 Br] with the diimines: N, N'-bis(2-amino-3-imino)methylenechromone-1,2-ethane (chret) and N,N ' -bis((3-chromone)methylene)benzene-1,2-diamine (chb) to afford a novel dinuclear rhenium(I) compound, fac-(Re(CO) 3 Br) 2 (m-chret) (1) and a mononuclear compound fac-[Re(CO) 3 (bzch)Br] (2) [bzch ¼ 2-benzimidazole-4H-chromen-4-one].…”

Section: Introductionmentioning

confidence: 97%

“…Furthermore, the facial tricarbonylrhenium(I) core has shown to serve as an ideal synthon for the formulation of new rhenium radiopharmaceuticals. This is illustrated by the facial tricarbonylrhenium(I) complexes stability under physiological conditions where the small size of the fac-[Re(CO) 3 ] þ core allows binding to various biological entities [5,6]. However, the next generation of potential rhenium radiopharmaceuticals requires chelators which can stabilize the metal centre both in the low and high oxidation states [7].…”

Section: Introductionmentioning

confidence: 98%

Formation, characterization and computational studies of mono- and dinuclear rhenium(I) chromone compounds

Ebinumoliseh

Booysen

Akerman

et al. 2016

Journal of Molecular Structure

View full text Add to dashboard Cite

Re(CO)3(H2O)3+ binding to lysozyme: structure and reactivity

Cited by 34 publications

References 47 publications

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Dose Effect of Rhenium (I)-diselenoether as Anticancer Drug in Resistant Breast Tumor-bearing Mice After Repeated Administrations

Fast infrared spectroscopy of protein dynamics: advancing sensitivity and selectivity

Formation, characterization and computational studies of mono- and dinuclear rhenium(I) chromone compounds

Contact Info

Product

Resources

About